The American Cancer Society (ACS) now recommends that men aged 50 to 69 undergo prostate-specific antigen (PSA) blood testing every two years to screen for prostate cancer.
This shift, the first update to the society’s guidance since 2010, aims to improve early detection rates for the nation’s second-leading cause of cancer death among men.
- Risk-Based Timing: Those with a family history or specific genetic markers, such as BRCA mutations, should begin annual testing at age 45.
- Diagnostic Nuance: An elevated PSA result does not confirm cancer; it necessitates secondary testing, such as magnetic resonance imaging (MRI) or biomarker analysis, before any biopsy is considered.
The updated ACS guidelines represent a fundamental change in how clinicians approach average-risk patients. Previously, the organization favored a shared decision-making model where physicians and patients discussed the risks of overdiagnosis and potential side effects of unnecessary treatment before proceeding with testing.
While elevated blood levels are a hallmark of potential malignancy, clinicians must distinguish between aggressive, life-threatening cancers and indolent tumors that may not progress during a patient's lifetime. The revised protocol integrates a multi-step verification process to mitigate the risk of false positives and unnecessary invasive procedures.
Black men, who face an approximately 70% higher incidence rate and double the mortality rate of white men following diagnosis, are now advised to begin annual PSA testing at age 45.
This age-based acceleration also applies to individuals with a strong family history of the disease or known genetic predispositions, such as BRCA gene mutations. By identifying these populations earlier, the ACS seeks to intervene before localized disease progresses to advanced stages where therapeutic options become more restrictive.
| Patient Demographic | Screening Frequency | Action Threshold |
|---|---|---|
| Average Risk (50–69) | Every 2 years | PSA ≥ 3.0 ng/mL |
| High Risk (45–69) | Annually | PSA ≥ 3.0 ng/mL |
| Older Adults (70–74) | Clinician-led discussion | PSA ≥ 6.5 ng/mL |
The guidelines advise against routine testing for men aged 75 and older, or those with a life expectancy of less than 10 years, as the clinical burden of treatment often outweighs the benefits of early detection in these cohorts.
Patients should consult their primary care physician if they experience persistent urinary symptoms, such as frequency or difficulty, though these are often indicative of benign conditions like benign prostatic hyperplasia (BPH) rather than malignancy. If a PSA test indicates a high level, the new protocol mandates a secondary blood test two to three months later to confirm the elevation before proceeding to diagnostic imaging or potential biopsy.
The 2010 guidelines previously left the decision entirely to individual patient-physician consultation, whereas the current policy provides a more structured framework for clinical practice.
